Biogen Pays $22M To Resolve Drug Co-Pay False Claims Suit
BOSTON — Biotechnology company Biogen Inc. has agreed to pay $22 million to resolve allegations that it violated the False Claims Act by using patient assistance foundations to cover patient co-pays...To view the full article, register now.
Already a subscriber? Click here to view full article